Highlights for the Three Months Ended August31, 2026

- Total revenues of $283 million and net income of $69 million

- Adjusted EBITDA(1) of $247 million

- Acquired 5 aircraft for $269 million, including 3 Airbus A321neo and 1 Boeing 737MAX8

- Sold 11 aircraft and other flight equipment for proceeds of $243 million and gains on sales of $38 million

- New technology aircraft comprised 54% of our fleet's net book value as of August 31, 2026

Liquidity

- Redeemed all 400 outstanding Series A Preference Shares

- 98% of total debt is unsecured as of August 31, 2026

- Adjusted net debt-to-equity of 2.4 times as of August 31, 2026

- Total liquidity of $2.8 billion as of October 1, 2026, which includes $2.0 billion of undrawn facilities, $0.7 billion of projected adjusted operating cash flows and sales through October 1, 2027, and $0.1 billion of unrestricted cash

- 259 unencumbered aircraft and other flight equipment with a net book value of $8.2 billion

STAMFORD, Conn., Oct. 14, 2026 /PRNewswire/ -- Mike Inglese, Aircastle's CEO stated, "Strong travel demand and constrained aircraft supply continue to support lease rates and asset values.  Significant gains on sale contributed to second quarter net income of $69 million, reinforcing a disciplined, profitability-focused approach to capital deployment.  Year-to-date, we've invested $386 million in aircraft acquisitions and we're moving into the second half of our fiscal year with ample liquidity and confidence in our ability to service our customers and source attractive investments."

Aviation Assets

As of August 31, 2026, Aircastle owned 263 aircraft and other flight equipment having a net book value of $8.3 billion and managed an additional 5 aircraft.

Conference Call

Following this press release, management will host a conference call on Wednesday, October 14, 2026, at 9:00 A.M. Eastern Time.  All interested parties are welcome to participate in the live call.  The conference call can be accessed by dialing 1 (800) 836-8184 (from within the U.S. and Canada) or +1 (646) 357-8785 (outside the U.S. and Canada) ten minutes prior to the scheduled start. Please reference our company name "Aircastle" when prompted by the operator.

A simultaneous webcast of the conference call will be available to the public on a listen-only basis at www.aircastle.com.  Please allow extra time prior to the call to visit the site and download the necessary software required to listen to the internet broadcast. 

For those who are not available to listen to the live call, a replay will be available on Aircastle's website shortly after the live call.

About Aircastle Limited

Aircastle Limited acquires, leases and sells commercial jet aircraft to airlines throughout the world.  As of August 31, 2026, Aircastle owned and managed 268 aircraft leased to 67 airline customers located in 42 countries.

Safe Harbor

All statements in this press release, other than characterizations of historical fact, are forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995.  Examples of forward-looking statements include, but are not necessarily limited to, statements relating to our proposed public offering of notes and our ability to acquire, sell, lease or finance aircraft, raise capital, pay dividends and increase revenues, earnings, EBITDA and Adjusted EBITDA and the global aviation industry and aircraft leasing sector. Words such as "anticipates," "expects," "enables," "intends," "plans," "positions," "projects," "believes," "may," "will," "would," "could," "should," "seeks," "estimates" and variations on these words and similar expressions are intended to identify such forward-looking statements.  These statements are based on our historical performance and that of our subsidiaries and on our current plans, estimates and expectations and are subject to a number of factors that could lead to actual results being materially different from those described in the forward-looking statements; Aircastle can give no assurance that its expectations will be attained.  Accordingly, you should not place undue reliance on any such forward-looking statements which are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated as of the date of this press release.  These risks or uncertainties include, but are not limited to, those described from time to time in Aircastle's filings with the SEC and previously disclosed under "Risk Factors" in Item 1A of Aircastle's most recent Form 10-K and any subsequent filings with the SEC.  In addition, new risks and uncertainties emerge from time to time, and it is not possible for Aircastle to predict or assess the impact of every factor that may cause its actual results to differ from those contained in any forward-looking statements.  Such forward-looking statements speak only as of the date of this press release.  Aircastle expressly disclaims any obligation to revise or update publicly any forward-looking statement to reflect future events or circumstances.

We define EBITDA as income (loss) from continuing operations before income taxes, interest expense, and depreciation and amortization.  We use EBITDA to assess our consolidated financial and operating performance, and we believe this non-U.S. GAAP measure is helpful in identifying trends in our performance.

This measure provides an assessment of controllable expenses and affords management the ability to make decisions which are expected to facilitate meeting current financial goals, as well as achieving optimal financial performance.  It provides an indicator for management to determine if adjustments to current spending decisions are needed.

EBITDA provides us with a measure of operating performance because it assists us in comparing our operating performance on a consistent basis as it removes the impact of our capital structure (primarily interest charges on our outstanding debt) and asset base (primarily depreciation and amortization) from our operating results.  Accordingly, this metric measures our financial performance based on operational factors that management can impact in the short-term, namely the cost structure, or expenses, of the organization.  EBITDA is one of the metrics used by senior management and the Board of Directors to review the consolidated financial performance of our business.

We define Adjusted EBITDA as EBITDA (as defined above) further adjusted to give effect to adjustments required in calculating covenant ratios and compliance as that term is defined in the indenture governing our senior unsecured notes.  Adjusted EBITDA is a material component of these covenants.

Contact:

Aircastle (Ireland) DAC (US)

Jim Connelly, SVP ESG & Corporate Communications

Tel: +1-203-504-1871

[email protected]

SOURCE Aircastle Ireland DAC

Share this article

—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)—

—New Analysis From the Phase 3 ASPEN Study at CHEST 2026 Provides Additional Insights on Bronchiectasis Management—

—Phase 3b ENCORE Study Findings at IDWeek 2026 Examine Amikacin and Macrolide Resistance Development in Patients With Newly Diagnosed Mycobacterium avium Complex (MAC) Lung Disease—

BRIDGEWATER, N.J., Oct. 14, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced new data from its respiratory portfolio will be presented at the American College of Chest Physicians® Annual Meeting 2026 (CHEST 2026), taking place Oct. 18–21 in Phoenix, and IDWeek 2026, taking place Oct. 21–24 in Washington, D.C.

"This fall medical congress season is a powerful reminder of what's possible when we stay focused on delivering meaningful solutions for patients who need them most," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "From CHEST 2026 to IDWeek 2026, we're proud to share data across our respiratory portfolio, including BRINSUPRI, TPIP, and ARIKAYCE. Altogether, these presentations reflect the strength and diversity of our growing respiratory portfolio and our unwavering dedication to advancing critical therapies that have the potential to benefit the patients we aim to serve."

Insmed's Presence at CHEST 2026

Presentation highlights at CHEST 2026 include four abstracts from the treprostinil palmitil inhalation powder (TPIP) clinical development program, including three late-breaking abstracts that offer new insights into the long-term potential of TPIP in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, a post hoc analysis of the Phase 3 ASPEN study of BRINSUPRI® (brensocatib) — the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB) — examines patient-reported sputum color and its association with neutrophil serine proteases and exacerbations.

The Insmed presentations at CHEST 2026 are as follows:

Top Late-Breaking Abstracts: New Drugs, New Targets, New Tools, Session ID 4145, Tuesday, Oct. 20, 2026, 11:15 a.m. MT to 12:15 p.m. MT (2:15 p.m. ET to 3:15 p.m. ET)

Late-Breaking Scientific Abstract Posters (B): Pulmonary Vascular Disease, Sleep Disorders, Poster 3219, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

Late-Breaking Scientific Abstract Posters (B): Pulmonary Vascular Disease, Sleep Disorders, Poster 3224, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

Pulmonary Vascular Disease Scientific Abstract Posters (C): PAH, Poster 3503, Tuesday, Oct. 20, 2026, 1:45 p.m. MT to 2:30 p.m. MT (4:45 p.m. ET to 5:30 p.m. ET)

Rapid Fire Original Investigation, CF and Non-CF Bronchiectasis Management, Session ID 4146, Monday, Oct. 19, 2026, 10:20 a.m. MT to 10:50 a.m. MT (1:20 p.m. ET to 1:50 p.m. ET)

Insmed's Presence at IDWeek 2026

Insmed will present two abstracts at IDWeek 2026 on ARIKAYCE® (amikacin liposome inhalation suspension), including data from the Phase 3b ENCORE study examining amikacin and macrolide resistance development in patients with newly diagnosed Mycobacterium avium complex (MAC) lung disease. A second presentation will examine real-world evidence on treatment drivers and outcomes in patients diagnosed with MAC lung disease.

Insmed presentations at IDWeek 2026 are as follows:

Antimicrobials, LB-2201.1, Thursday, Oct. 22, 2026, 10:30 a.m. ET to 10:42 a.m. ET

Respiratory Infections: Viral and Bacterial, P-475, Saturday, Oct. 24, 2026, 12:15 p.m. ET to 1:30 p.m. ET

About ARIKAYCE

ARIKAYCE® is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE™ liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira® Nebulizer System manufactured by PARI Pharma GmbH (PARI).

About PARI Pharma and the Lamira® Nebulizer System

ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve patient care.

About BRINSUPRI

BRINSUPRI® (brensocatib) is a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic airway inflammation in non-cystic fibrosis bronchiectasis (NCFB). The therapy is approved in the United States as BRINSUPRI (brensocatib 10 mg and 25 mg tablets) and indicated for the treatment of NCFB in adult and pediatric patients 12 years of age or older. In the European Union and United Kingdom, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. In Japan, BRINSUPRI Tablets 25 mg (brensocatib hydrate) is approved for the treatment of NCFB in adults and pediatric patients 12 years and older.

About TPIP

Treprostinil palmitil inhalation powder (TPIP) is an investigational dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil linked by an ester bond to a 16-carbon chain. Designed entirely in Insmed's laboratories, TPIP is a potentially highly differentiated prostanoid being developed as once-daily therapy for the treatment of patients with pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF), and idiopathic pulmonary fibrosis (IPF). TPIP is administered in a capsule-based inhalation device. TPIP is an investigational drug product that has not been approved for any indication in any jurisdiction.

BOXED WARNING AND IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.

Hypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in the clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (3.1%) compared to patients treated with a background regimen alone (0%). Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE and manage patients as medically appropriate.

Hemoptysis has been reported with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). If hemoptysis occurs, manage patients as medically appropriate.

Bronchospasm has been reported with the use of ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (28.7%) compared to patients treated with a background regimen alone (10.7%). If bronchospasm occurs during the use of ARIKAYCE, treat patients as medically appropriate.

Exacerbations of underlying pulmonary disease has been reported with the use of ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease (reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis) have been reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients treated with background regimen alone (9.8%). If exacerbations of underlying pulmonary disease occur during the use of ARIKAYCE, treat patients as medically appropriate.

Anaphylaxis and Hypersensitivity Reactions: Serious and potentially life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients taking ARIKAYCE. Signs and symptoms include acute onset of skin and mucosal tissue hypersensitivity reactions (hives, itching, flushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of breath, wheezing, stridor, cough), gastrointestinal symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and symptoms of anaphylaxis (tachycardia, low blood pressure, syncope, incontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate for previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or a hypersensitivity reaction occurs, discontinue ARIKAYCE and institute appropriate supportive measures.

EcoPhage and Agricultura Nacional Sign a Distribution Agreement for Mexico

Strategic partnership will bring EcoPhage's phage-based biological crop protection solutions to Mexican growers

REHOVOT, Israel, Oct. 14, 2026 /PRNewswire/ -- EcoPhage, a leader in the development of sustainable phage-based biopesticides for the control of bacterial plant diseases, today announced that it has entered into a distribution agreement with Agricultura Nacional, S.A. de C.V. ("Dragon") for the distribution, marketing and sale of EcoPhage's products in Mexico.

The agreement marks an important milestone in EcoPhage's international commercial expansion and establishes Dragon as EcoPhage's distribution partner in Mexico, subject to the achievement of agreed commercial targets.

Under the agreement, Dragon will initially distribute GoldenEco® and EcoFire®, two of EcoPhage's phage-based biological crop protection products designed to address important bacterial diseases affecting agricultural crops.

Bacterial diseases represent a significant challenge for growers worldwide, while available disease-management programs have traditionally relied heavily on copper-based products and, in certain applications, antibiotics. Growing concerns around resistance, environmental impact, residues and evolving regulatory requirements are increasing the demand for innovative biological alternatives.

EcoPhage's proprietary technology platform uses naturally occurring bacteriophages—viruses that specifically target and destroy bacteria—to develop targeted biological solutions for bacterial plant diseases.

The company's pipeline includes products designed for multiple crops and bacterial pathogens, with the objective of providing growers with effective, targeted and sustainable tools that can complement existing crop-protection programs.

GoldenEco®, EcoPhage's flagship product that was approved recently by the EPA in the USA, is being developed for the management of bacterial diseases in tomatoes and peppers. The product is based on bacteriophage technology and is designed to provide growers with a biological approach to bacterial disease management. EcoFire® is another product in EcoPhage's expanding portfolio of phage-based solutions, targeting bacterial disease management in fruit crops.

Through the agreement, Dragon will be responsible for the marketing and distribution of EcoPhage's products throughout Mexico, working to establish the products in the local agricultural market and expand access to phage-based biological crop protection solutions.

The partnership combines EcoPhage's proprietary phage technology and product development capabilities with Dragon's local market expertise, commercial infrastructure and agricultural relationships, creating a platform for the introduction and expansion of innovative biological crop protection solutions in Mexico.

Martin Fueyo Mac Donald, Dragon's CEO, said: "We are excited to partner with EcoPhage and bring its innovative phage-based technology to the Mexican agricultural market. The demand for effective and sustainable crop protection solutions continues to grow, and we believe EcoPhage's technology offers an important new approach to bacterial disease management. We look forward to working closely with EcoPhage to introduce these solutions to Mexican growers and build a strong commercial presence in the market."

"We are very pleased to enter into this strategic partnership with Dragon," added Guy Elitzur, CEO of EcoPhage. "Mexico is an important agricultural market with significant potential for biological crop protection solutions, and we believe Dragon is the right partner to introduce and develop our technology in the country. This agreement represents an important step in our global commercialization strategy and brings EcoPhage closer to growers who are looking for new and sustainable solutions to manage bacterial diseases."

The partnership reflects the growing importance of biological solutions as part of integrated crop protection programs. By providing growers with access to targeted, phage-based products, EcoPhage and Dragon aim to support the development of more sustainable disease-management programs and provide additional tools that can help reduce reliance on conventional approaches where appropriate.

"Our vision is to build a global platform of biological solutions for bacterial diseases," added Elitzur. "The partnership with Dragon is an important part of that vision. We are not only introducing individual products to a new market; we are building a long-term commercial platform that can support the introduction of additional EcoPhage technologies and products to Mexican agriculture."

About Agricultura Nacional, S.A. de C.V.

Agricultura Nacional, S.A. de C.V. (ANSA) is a Mexican agricultural company serving the country's crop protection and agricultural markets. Through its commercial capabilities and local market expertise, ANSA provides agricultural solutions to growers and supports the adoption of innovative technologies in Mexican agriculture.

About EcoPhage

EcoPhage is an agricultural biotechnology company developing innovative biological solutions for the control of bacterial plant diseases. Based on its proprietary phage discovery and development platform, EcoPhage develops targeted, natural, non-GMO and zero-residue biopesticides designed to provide effective disease management across a broad range of crops.

The company is advancing a growing pipeline of phage-based products targeting important bacterial diseases and is focused on delivering sustainable solutions that support growers and the future of modern agriculture.

Media Contact:

Email: [email protected]

SOURCE EcoPhage

Share this article

Bank of America Reports Third Quarter 2026 Financial Results

CHARLOTTE, N.C., Oct. 14, 2026 /PRNewswire/ -- Bank of America reported its third quarter 2026 financial results today. The news release, supplemental filing and investor presentation can be accessed at Bank of America's Investor Relations website at https://investor.bankofamerica.com/quarterly-earnings.

A Form 8-K containing Bank of America's financial results is also available at the U.S. Securities and Exchange Commission's website at https://www.sec.gov.

Investor Conference Call information

Chair and CEO Brian Moynihan and Executive Vice President and CFO Alastair Borthwick will discuss the financial results in an investor conference call at 8:30 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call.

Investors can listen to live audio of the conference call and view the presentation slides by visiting the "Events and Presentations" section of the company's Investor Relations website.

Replay information for Investor Conference Call

Investors can access replays of the investor conference call by visiting the Investor Relations website or by calling 1.800.934.4850 (U.S.) or 1.402.220.1178 (international) from noon on October 14 through 11:59 p.m. ET on October 23. 

Bank of America

Bank of America is one of the world's leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving more than 69 million clients with approximately 3,500 retail financial centers, approximately 15,000 ATMs (automated teller machines) and award-winning digital banking with approximately 60 million verified digital users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. As the #1 small business lender in the United States (FDIC), Bank of America offers industry-leading support to approximately 4 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and more than 35 countries and/or jurisdictions. Bank of America Corporation stock (NYSE: BAC) is listed on the New York Stock Exchange.

Investors may contact

Lee McEntire, Bank of America

Phone: 1.980.388.6780

[email protected]

Jonathan G. Blum, Bank of America (Fixed Income)

Phone: 1.212.449.3112

[email protected]

Reporters may contact

Jocelyn Seidenfeld, Bank of America

Phone: 1.646.743.3356

[email protected] 

SOURCE Bank of America Corporation

Share this article

TELUS Digital Partners with Parloa to Help Enterprises Build and Manage AI Agents for Stronger Customer Relationships

Collaboration pairs Parloa's platform with TELUS Digital's customer experience expertise to help improve first impressions, deepen engagement and create value for enterprises and their customers

VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- TELUS Digital, a global technology service provider specializing in AI-powered digital customer experiences (CX) and future-focused digital transformations, today announced a partnership with Parloa, the leading agentic CX enabler for the enterprise. Established in Germany, Parloa brings a robust European enterprise footprint and experience supporting deployments subject to the General Data Protection Regulation (GDPR) and other European regulatory requirements, while TELUS Digital offers its existing delivery presence and regulated-industry expertise across North America and Europe.

TELUS Digital will serve as an implementation partner, introducing prospective and current enterprise clients to Parloa's AI agent platform and helping them put it into production at scale. Enterprises that choose to deploy Parloa can contract directly with the company for the platform itself and engage TELUS Digital for implementation, integration, change management, managed services and other professional services.

Parloa's AI agents handle customer interactions such as authentication, bookings, payments and order inquiries from beginning to end, and escalate to a human agent when a conversation calls for high-touch care. Parloa's own research, a study evaluating 10,000 enterprise websites and 4,000 chat interactions, found that fewer than 9% of chatbot conversations reached resolution, and only about 10% of escalation attempts actually reached a human agent. Separately, Parloa's Consumer Patience Index, a survey of 1,001 U.S. consumers conducted by independent research firm Propeller Insights, found that nearly a third of consumers would switch brands entirely just to avoid being put on hold. Parloa's approach is built on the idea that completing an interaction, rather than stalling partway through it, can turn automation into customer loyalty instead of frustration.

"The research confirms what we've all experienced ourselves — consumer expectations are high, and brand loyalty is fragile," said Chris Silver, Chief Revenue Officer, Parloa. "They need to have their issue solved, the first time, on their preferred channel and with no unnecessary delays. Legacy automation couldn't do it; Parloa's can, and with our TELUS Digital partnership, we're excited to show the innovative enterprise what's possible in agentic customer experience."

Automation in CX can be most effective when enterprises and customers trust the platform delivering it. Parloa's platform recently earned SAP's endorsed app premium certification, a distinct category within SAP's partner ecosystem reserved for solutions that meet added security, testing and performance standards. The platform runs on Azure and supports multiple AI models, including OpenAI's GPT series, giving enterprises flexibility as the technology evolves. The company, with enterprise operations across Europe and the U.S., has built six years of deployment experience serving businesses across banking and financial services, insurance, utilities, telecommunications and media, retail, logistics, travel, and healthcare and life sciences. Parloa builds its agents to meet enterprise compliance standards, including GDPR, ISO 27001 and SOC 2, with every interaction designed to help protect personal information.

Expanding TELUS Digital's AI-powered CX solutions

As enterprises adopt agentic AI platforms across their customer service operations, TELUS Digital believes a single tool rarely covers every need and that enterprises benefit from matching the right capability to the right type of interaction.

"When contact centers get buried in high volume, repetitive interactions, we often see cost to serve climb without the customer experience improving," said Will Mayo, Global Senior Vice President of Growth, TELUS Digital. "What stands out to us about Parloa is that its agents are designed to take care of routine requests from start to finish, and hand-off to a person when a conversation gets more complex. Parloa is built to work through partners like TELUS Digital, which can act as a one-stop shop from strategy to implementation and scaled delivery. This gives our clients another way to move eligible, high volume interactions to automation while keeping people available for conversations that need their empathy and knowledge."

The Parloa partnership is the newest addition to TELUS Digital's AI capabilities for customer experience. TELUS Digital's conversational AI solutions combine voice, generative AI and agentic automation, so AI agents can handle routine requests across channels and languages and pass the conversation to a human agent, with full context, when the interaction needs a person.

To support human agents, TELUS Digital's AI-powered agent tools can analyze customer interactions to support quality and coaching, and offer real-time guidance during live conversations. TELUS Digital's proprietary Fuel iX™ Agent Assist gives agents real-time knowledge and answers, while Fuel iX Agent Trainer uses AI-generated voice and chat simulations to help new agents practice customer conversations before taking live calls. TELUS Digital can connect these solutions to clients' contact center platforms, customer relationship management (CRM) systems and backend systems. The company also offers CX consulting to identify where AI fits, along with customer service and contact center management teams to run and optimize a blend of AI and human support.

The Parloa partnership extends TELUS Digital's AI-powered CX solutions for enterprise clients in industries including telecommunications, retail, travel and hospitality, media, banking, financial services and insurance, and healthcare, supported by a global delivery footprint of 83,000+ team members across 35+ countries.

To learn more about TELUS Digital's AI-powered CX solutions, visit:

For more information on Parloa's agentic AI platform for CX, visit: parloa.com

Frequently asked questions

- What is Parloa and what does it do?

Parloa is an agentic AI platform built to let AI agents handle customer interactions such as authentication, bookings, payments and order inquiries from beginning to end. The platform escalates to a person when a conversation calls for more judgment, and every interaction is designed to protect personal information while meeting compliance standards including built to support GDPR and certified to ISO 27001 and SOC 2. Parloa also holds SAP's endorsed app premium certification, a distinct category within SAP's partner ecosystem for solutions that meet added security, testing and performance standards. The platform is built around turning every resolved interaction into lasting customer loyalty, not just a closed ticket.

- Why did TELUS Digital partner with Parloa?

TELUS Digital partnered with Parloa to expand its portfolio of AI capabilities for customer experience with end-to-end customer service automation solutions. The partnership pairs Parloa's agentic AI platform, used by enterprises in insurance, retail, travel and healthcare, with TELUS Digital's CX expertise, industry relationships and global delivery footprint. It also complements the AI solutions TELUS Digital already offers, giving enterprises another way to move eligible, high volume interactions to automation while keeping people available for the conversations that need them.

- What problem does agentic AI solve for contact centers?

Contact centers often carry a heavy load of repetitive, transactional interactions, such as identity verification, bookings and payment questions, that drive up the cost to serve without making the experience any better for the customer. Many AI tools can answer part of a question but still hand the interaction back to a person to finish, so the customer effectively waits twice. Parloa's own research found that fewer than 9% of chatbot conversations reach resolution, illustrating how common that gap is. Agentic AI platforms like Parloa are built to complete these interactions fully on their own, reserving human involvement for the conversations that need empathy and judgment.

- Who implements Parloa for TELUS Digital's enterprise clients?

Enterprises that choose to deploy Parloa can contract directly with the company for the platform itself and engage TELUS Digital for implementation, integration, change management, managed services and other professional services. TELUS Digital serves as an implementation partner, introducing prospective and current enterprise clients to Parloa's AI agent platform and helping them put it into production at scale.

- What does TELUS Digital's approach to AI in customer experience look like? TELUS Digital's AI portfolio for customer experience pairs its own Fuel iX suite with technology partnerships, covering conversational AI agents, real-time guidance and coaching for human agents, and agent training. Parloa expands that portfolio with autonomous resolution for eligible transactional interactions. These sit alongside TELUS Digital's broader CX practice, spanning consulting-led AI transformation, contact center operations and technology implementation for enterprise clients across industries including telecom, banking and financial services, media and entertainment, hi-tech, retail, travel, transport and hospitality, software and platforms, energy and utilities, healthcare, and insurance, backed by a global delivery footprint of 83,000+ team members across 35+ countries.

- Why should enterprises choose TELUS Digital as a Parloa implementation partner?

Highlights:

- Impressive silver and gold recoveries achieved from the latest round of optimised cyanide leach testwork at the Maverick Silver Project, demonstrating rapid silver and gold extraction within 24 to 48 hours.

- The Company is undertaking a range of metallurgical testwork to optimise silver-gold extraction and provide optionality in processing pathways that will be considered in future studies.

- Sample 1 (LT15) achieved rapid silver and gold extraction within 24 hours under the same leach conditions (P80 53µm grind; 5,000 ppm initial / 2,500 ppm-maintained NaCN; no lead nitrate): 

- Head assay results, 84.5% silver and 83.6% gold recovery with peak recoveries indicated between 0 and 48 hours.

- A lower-reagent optimisation test on Sample 2 (LT22) also delivered rapid silver extraction (P80 53µm grind; 3,000 ppm initial / 1,500 ppm-maintained NaCN; 500 ppm lead nitrate): 

- Head assay results, 87.7% silver recovery and 87.5% gold recovery with peak recoveries indicated between 0 hours and 48 hours.

- Possible upside exists for silver and gold recoveries at 24 and 48 hours, with Sample 1 interim solution assays indicating higher extraction percentages than the reported recoveries calculated using final head assay grades.

- Silver extraction accelerated under elevated cyanide, with further optimisation targeting the optimal balance between recovery and reagent consumption.

- Tank-leach/CIL may provide greater flexibility for potential antimony recovery. The Company is in the process of working towards a maiden antimony Mineral Resource Estimate.

- Continued active U.S. Government (Department of Commerce) engagement, focused on large-scale domestic development and maximising U.S. production of silver and critical minerals including antimony and gold, further reinforces the strategic rationale for also evaluating higher recovery tank leach/CIL development pathways at Maverick.

PERTH, Australia, Oct. 14, 2026 /PRNewswire/ -- Sun Silver Limited (ASX: SS1; OTCQX: SSLVF) ("Sun Silver" or "the Company") is pleased to report highly encouraging results from its ongoing metallurgical activities for the Maverick Silver Project in Nevada, USA ("Maverick" or "the Project").

Sun Silver Managing Director, Andrew Dornan, said:

"These results continue to demonstrate the strong metallurgical characteristics of Maverick, with rapid silver and gold extraction within just 24 hours providing further confidence in the Project's development potential. The results highlight clear opportunities to further optimise recoveries, reagent consumption and processing conditions as we evaluate the optimal development pathway. With active U.S. Government engagement focused on large-scale domestic development, maximising U.S. metal production and strengthening critical mineral supply chains, we continue to evaluate processing options capable of maximising silver, gold and potential antimony recovery."

Metallurgical Testwork - Update

As part of the Company's larger ongoing metallurgical testwork program evaluating and optimising potential processing pathways for the Project, the work detailed within this announcement focused specifically on accelerating silver extraction within the first 48 hours through optimisation of cyanide concentration, lead nitrate addition, dissolved oxygen and grind size.

This series of testwork was devised to build on and complement the previous exceptional silver-gold recovery results from Intermittent Bottle Roll and Cyanide Leach testwork that provided an initial estimate of heap-leach and tank-leach recoveries, respectively, and showed no evidence of preg-robbing .

Metallurgical testwork was designed, undertaken, managed and reviewed by Independent Metallurgical Operations ("IMO"), a subsidiary of SGS. Samples utilised for this testwork were derived from the same composites of the initial testwork program1. The tests were conducted in deionised water, so it mitigates against known chloride ion concentration variations in Perth tap water.

A total of 242 intervals of half diamond drill core were derived from existing diamond core samples, comprising oxide and transitional mineralisation. Two composite samples were prepared:

- Composite sample 1: 147kg total weight

- Composite sample 2: 127kg total weight

Five cyanide leach bottle-roll tests were undertaken on Sample 1 and six tests on Sample 2, allowing the Company to assess the effect of varying reagent regimes and grind sizes on silver and gold extraction.

The standout result was achieved from Sample 1 (LT15), which demonstrated rapid extraction of both silver and gold under the LT15 leach conditions.

Head assay results, 84.5% silver and 83.6% gold recovery with peak recoveries indicated between 0 hours and 48 hours.

The rapid extraction of both silver and gold within the first 24 to 48 hours is particularly encouraging for the Company's assessment of a conventional tank-leach/CIL processing flowsheet, where recovery, leach kinetics and residence time are important inputs into process design and economic evaluation.

Strong Recoveries at Reduced Cyanide Dosage

Importantly, a subsequent optimisation test on Sample 2 (LT22) evaluated silver-gold recovery under a more moderate cyanide regime combined with a reduced lead nitrate dosage.

Head assay results, 87.6% silver recovery and 87.5% gold recovery

The ongoing program will seek to determine whether a balanced combination of cyanide and lead nitrate can deliver comparable metallurgical performance to the higher cyanide regime while reducing overall reagent consumption and operating costs.

Lead Nitrate and Early-Stage Leach Kinetics

Comparative tests assessed the introduction of lead nitrate as a potential means of accelerating silver and gold leach kinetics.

Testwork shows that the addition of lead nitrate under standard cyanide conditions accelerated silver extraction in both samples, supporting further assessment of lead nitrate as part of reagent optimisation.

At elevated cyanide concentrations, the incremental benefit of lead nitrate reduced materially by 48 hours. In Sample 1, lead nitrate accelerated early silver extraction, while the 48-hour silver recoveries were similar between the tests, indicating that its principal benefit under the conditions tested was accelerated early-stage extraction.

Silver Leach and Reagent Optimisation

The Maverick testwork demonstrates the impact of cyanide concentration on the rate of silver extraction.

Silver cyanidation can require more intensive leach conditions than conventional free-milling gold cyanidation. Silver extraction can be sensitive to free cyanide concentration, dissolved oxygen, mineralogy and leach residence time, making optimisation of the overall reagent regime an important component of flowsheet development.

These results highlight an important optimisation opportunity for Maverick: determining the optimum balance between cyanide concentration, lead nitrate dosage, dissolved oxygen and residence time to maximise silver and gold recovery and leach kinetics while minimising reagent consumption and processing costs.

Tank Leach Provides Potential High-Recovery Development Pathway

The latest results provide further support for Sun Silver's assessment of a conventional tank-leach/CIL processing pathway, alongside heap-leach development scenarios currently being evaluated for Maverick.

The ability to achieve 84.5% silver and 83.6% gold recovery within only 24 hours (Sample 1 results) provides an important technical basis for evaluating a high-recovery processing configuration.

The Company considers the speed of extraction particularly encouraging. The majority of recoverable silver and gold in the standout test was extracted within the first 24 hours. This provides important information for ongoing optimisation of residence time, plant configuration and processing economics.

Recovery Disclosure: Silver and gold extraction percentages reported at interim time intervals (including 24 and 48 hours) represent indicative point-in-time calculated extractions, determined from solution assays collected at the relevant sampling time and the back-calculated head grade. Accordingly, interim extraction results are indicative of metallurgical performance at the stated point-in-time and should not be interpreted as final or ultimate recoveries.

U.S. Strategic Importance and Optionality for Antimony Recovery

Sun Silver continues active engagement with various U.S. Government including Department of Commerce and Permitting Council regarding Maverick's potential role in strengthening domestic silver and critical-mineral supply chains, including potential pathways for U.S. Government support for the Project.

These engagements reflect a strategic focus on large-scale domestic development and maximising the recovery and production of U.S. sourced metals. Together with Maverick's substantial silver-gold Mineral Resource and emerging antimony potential, this reinforces the importance of evaluating development scenarios capable of maximising metal recovery and production at scale.

Accordingly, the Company is continuing to evaluate both heap-leach and higher-recovery tank-leach/CIL processing pathways, including the potential for a tank-leach/CIL flowsheet to provide greater flexibility for potential future antimony recovery. All development options remain open, with metallurgical, technical and economic investigations continuing to determine the optimal development pathway for Maverick.

Next Phase of Tank-Leach / CIL Metallurgical Optimisation

The latest testwork has identified several clear opportunities to further optimise the Maverick processing flowsheet, with the next phase of metallurgical work focused on maximising recoveries while reducing reagent consumption, grind requirements and processing costs.

MEMPHIS, Tenn., Oct. 14, 2026 /PRNewswire/ -- International Paper (NYSE: IP; LSE: IPC), a leader in sustainable packaging solutions, announces that its EMEA Packaging Business leadership team will hold a Capital Markets Day in London on November 3, 2026, 13:00 – 17:00 GMT (8:00 a.m. – 12:00 p.m. ET).

International Paper has made significant progress preparing to separate its EMEA Packaging Business into an independent, publicly traded company (the "Separation"). Once the Separation is complete, the independent company will be known as DS Smith plc.

Tim Nicholls and Vincent Bonnot, the future Chief Executive Officer and future Chief Financial Officer of DS Smith plc, respectively, will host the Capital Markets Day, alongside other senior leaders from across the EMEA business. The team will discuss the planned public company and its position as an enhanced pure-play packaging leader within the European market. The team will also provide details about the business model, growth strategy, and financial outlook post Separation.

The event will be available via webcast, and a recording will be provided on DS Smith's website upon event completion.

To register for the webcast please visit: https://stream.brrmedia.co.uk/broadcast/6aa9548bba91570013153fcd

If you wish to attend in person, please contact [email protected].

Separation Update

DS Smith plc is expected to be separated by way of a spin off, through the listing of the business on the London Stock Exchange with a Level II ADR program to be listed on the New York Stock Exchange.

The Separation remains subject to the satisfaction of customary conditions, including final approval by the International Paper Board of Directors as well as the filing and effectiveness of a registration statement with the U.S. Securities and Exchange Commission (the "SEC") and the publication of a prospectus approved by the U.K. Financial Conduct Authority (the "FCA"). No assurance can be provided regarding the ultimate timing or structure of the proposed Separation or its eventual completion.

About International Paper (NYSE: IP; LSE: IPC)

International Paper creates sustainable packaging solutions that enable our customers, teammates and shareowners to thrive in an ever-changing world. We are a leader in corrugated packaging, partnering with customers across industries to protect what matters most, strengthen supply chains and create lasting value. Learn more at internationalpaper.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the use of forward-looking or conditional words such as "expects," "anticipates," "believes," "estimates," "could," "should," "can," "forecast," "outlook," "intend," "look," "may," "will," "remain," "confident," "commit" and "plan" or similar expressions. These forward-looking statements reflect management's current views and are subject to risks and uncertainties that could cause actual results and the timing of events to differ materially from those expressed or implied in these forward-looking statements. These risks and uncertainties include the risks that this planned Separation of the Company's North America and EMEA operations into two independent public companies will not happen on a timely basis or at all, the Company's ability to achieve the desired outcome and realize the anticipated benefits from the Separation and the potential uncertainty and disruption during the pendency of the Separation. These forward-looking statements are also subject to the risks and uncertainties contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on February 27, 2026, and subsequent reports filed with the SEC. In addition, other risks and uncertainties not presently known to the Company or that we currently believe to be immaterial could affect the accuracy of any forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements contained in this press release, whether as a result of new information, future events or changes in expectations.

SOURCE International Paper

Share this article

MIRACELL to Host Stem Cell Science Day 2026 in Los Angeles, Featuring International Clinical Insights in Regenerative Medicine

- Leading South Korean and U.S. medical experts to share clinical insights into regenerative medicine

- Austrian clinical study on 47 ACL rupture patients treated with SMART M-CELL published in peer-reviewed journal

LOS ANGELES, Oct. 14, 2026 /PRNewswire/ -- Miracell U.S. Inc., the U.S. subsidiary of South Korean stem cell technology pioneer Miracell, will host "Stem Cell Science Day 2026," a specialized seminar on regenerative medicine, in Los Angeles, California, on Sunday, Nov. 1.

The seminar will bring together medical professionals from South Korea and the United States to present the latest research developments and clinical findings in stem cell-based therapies. Participants will explore real-world clinical applications and potential healthcare integration of Miracell's proprietary SMART M-CELL system in the U.S.

The event will take place from 1:00 p.m. to 7:00 p.m. at The Equitable Building (14th Floor) on Wilshire Boulevard in Los Angeles. It is open to healthcare professionals—including physicians (MD/DO), nurse practitioners (NP), physician assistants (PA), and registered nurses (RN)—free of charge.

Leading Medical Experts to Present Advances in Regenerative Medicine

The seminar features three prominent practitioners from South Korea and the U.S. who will present emerging research and clinical outcomes across women's health, orthopedics, and anti-aging medicine:

- Tae-hee Kim, M.D., Ph.D., Professor of Obstetrics and Gynecology at Soonchunhyang University Bucheon Hospital, will present "The Future of Women's Health and Regenerative Medicine," highlighting recent scientific breakthroughs and novel therapeutic approaches.

- Alex Kim, M.D., Director of the TIME Anti-Aging and Hair Transplant Center in the U.S., will discuss "Global Trends in Stem Cell Therapy and Regenerative Approaches in Orthopedics," drawing from his extensive clinical practice in the United States.

- Sung-Wook Choi, M.D., Ph.D., Professor of Orthopedic Surgery at Jeju National University, will share clinical cases and therapeutic applications using Miracell's SMART M-CELL stem cell isolation and concentration system.

International Study Highlights Clinical Outcomes of SMART M-CELL for ACL Injuries

Miracell's SMART M-CELL system continues to gain global academic traction. A research team led by Patrick Weninger, M.D., an orthopedic specialist in Vienna, Austria, recently published findings from a clinical study involving 47 patients with anterior cruciate ligament (ACL) ruptures (mean age: 28.1 years) in the SCIE-indexed Indian Journal of Orthopaedics (July 2026).

The study—titled "Autologous Peripheral Blood-Derived Stem Cells Combined with Platelet-Rich Plasma is Associated With Clinical and Radiological Improvement in Anterior Cruciate Ligament Ruptures—Preliminary Clinical and MRI Findings in 47 Consecutive Patients"—evaluated a non-surgical treatment combining autologous blood-derived cells and platelet-rich plasma (PRP).

Using the SMART M-CELL system, researchers isolated and concentrated CD34+-containing blood-derived stem cells (BSCs) from each patient. Combined with PRP, the preparation was administered to the injured ligament in a single non-surgical session. Over a 12-month follow-up period:

- 46 out of 47 patients successfully returned to their pre-injury sports activity levels.

- Patients demonstrated significant pain reduction, improved knee function, and positive structural restoration on MRI scans.

These findings highlight the potential of a tissue-preserving, biological approach to ACL management—offering an effective non-surgical alternative for selected patients.

U.S. Expansion and Global Collaboration

SMART M-CELL is an advanced cell separation system engineered to process autologous blood and bone marrow. In April 2026, Miracell received 510(k) clearance from the U.S. FDA for its SMART M-CELL blood-derived stem cell (BSC) and bone marrow-derived stem cell (BmSC) concentration systems and dedicated kits, establishing a solid foundation for its entry into the U.S. market.

Beyond clinical presentations, Stem Cell Science Day 2026 will feature panel discussions, interactive Q&A sessions, one-on-one consultations, and networking opportunities designed to foster long-term international collaboration in regenerative medicine.

Event Details

- Event: Stem Cell Science Day 2026

- Date: Sunday, November 1, 2026

- Time: 1:00 p.m. – 7:00 p.m. PDT (Los Angeles time)

- Venue: The Equitable Building, 14th Floor

- Address: 3435 Wilshire Blvd., Suite 1400, Los Angeles, CA 90010

- Target Audience: Physicians and Licensed Healthcare Professionals (MD, DO, NP, PA, RN)

- Admission: Free (Advance registration required; limited seating)

- Organizer: Miracell U.S. Inc.

- RSVP & Inquiries:[email protected] | +1 213-318-8839

- Website:www.mira-cell.us

SOURCE Miracell

Share this article

Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets

MCLEAN, Va., Oct. 14, 2026 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, aircraft surveillance, and positioning, navigation, and timing (PNT) satellite services, today announced that Altair Semiconductor, a world leader in cellular IoT chips, is integrating Iridium NTN Direct℠ capability into Altair's ALT1350 and next-generation ALT1550 IoT chipset platforms. With terrestrial cellular IoT and Iridium satellite connectivity on a single chipset, device manufacturers, module makers and mobile network operators (MNOs) will be able to extend IoT connectivity beyond the reach of terrestrial networks through the Iridium satellite network, without adding a separate satellite modem to their designs.

The partnership combines Altair's cellular IoT chipset technology, among the most highly integrated low-power connectivity solutions available, with Iridium's 3GPP standards-based non-terrestrial network (NTN) service, giving device manufacturers another chipset option for products that need connectivity beyond terrestrial cellular coverage. With the ultra-low-power ALT1350, these connectivity requirements can include asset tracking, logistics, smart metering and utilities, agriculture, vehicle telematics, industrial monitoring and remote infrastructure. With the ALT1550, these capabilities extend to a new generation of AI-powered 5G eRedCap devices, such as smart glasses, AI assistants and other wearables, that need to stay connected wherever they go.

"Altair has deep experience developing highly integrated, low-power IoT solutions, and we're excited to work together to extend their reach with Iridium's truly global satellite network," said Tim Last, executive vice president, Iridium. "As a market leader in satellite IoT, Iridium is offering device manufacturers a powerful new way to develop connected products. Integrating Iridium NTN Direct into Altair's chipsets will enable solutions and applications that require reliable, low-power connectivity beyond the limits of terrestrial networks."

"Adding Iridium NTN Direct to our ultra-low-power LTE-M/NB-IoT ALT1350 and 5G eRedCap ALT1550 chipsets reflects our commitment to giving customers greater flexibility in how and where their IoT devices connect," said Dima Feldman, VP Product Management and Marketing, Altair Semiconductor. "With Iridium's truly global LEO satellite connectivity alongside terrestrial cellular, device manufacturers can more easily develop solutions that will reliably work anywhere they're deployed."

Iridium NTN Direct leverages Iridium's fully operational, LEO satellite constellation and globally coordinated L-band spectrum to extend standards-based connectivity beyond terrestrial networks. The service is designed to support NB-IoT and direct-to-device (D2D) applications using compatible 3GPP standards-based chipsets, providing MNOs, chipset manufacturers and device makers with a path to extend connectivity through the Iridium satellite network.

Altair joins a growing ecosystem of partners bringing the Iridium NTN Direct service to market. A combination of chipmakers, module manufacturers, OEMs, device makers, and IoT developers is leading the next generation of NTN-cellular integration with Iridium NTN Direct.

For more information about Iridium NTN Direct, visit www.iridium.com/ntn-direct

About Iridium Communications Inc.

Iridium Communications Inc. (Nasdaq: IRDM) operates the world's only truly global mobile satellite network. It serves as a platform for innovation, enabling voice, data, and messaging, positioning, navigation, and timing (PNT), and aircraft surveillance services anywhere on Earth. Through its satellite constellation and integrated capabilities like Aireon, the world's only space-based air traffic surveillance system, Iridium delivers services that support safety-focused operations across aviation, maritime, government, industrial, and consumer markets. The company is a leader in satellite Internet of Things (IoT) connectivity and is advancing direct-to-device (D2D) communications based on open standards to expand access to satellite services.

Headquartered in McLean, Virginia, Iridium innovates through an ecosystem of more than 500 technology and distribution partners, serving millions of customers worldwide. For more information visit www.iridium.com.

Forward-Looking Statements Disclosure

Statements in this press release that are not purely historical facts may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The company has based these statements on its current expectations and the information currently available to us. Forward-looking statements in this press release include statements regarding the capabilities, benefits and availability of the Iridium NTN Direct service. Forward-looking statements can be identified by the words "anticipates," "may," "can," "believes," "expects," "projects," "intends," "likely," "will," "to be" and other expressions that are predictions or indicate future events, trends or prospects. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Iridium to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties regarding the timing of commercial availability of the Iridium NTN Direct service, the company's ability to maintain the health, capacity and content of its satellite constellation, general industry and economic conditions, and competitive, legal, governmental and technological factors. Other factors that could cause actual results to differ materially from those indicated by the forward-looking statements include those factors listed under the caption "Risk Factors" in the company's Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on February 12, 2026, and the company's Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 22, 2026, as well as other filings Iridium makes with the SEC from time to time. There is no assurance that Iridium's expectations will be realized. If one or more of these risks or uncertainties materialize, or if Iridium's underlying assumptions prove incorrect, actual results may vary materially from those expected, estimated or projected. Iridium's forward-looking statements speak only as of the date of this press release, and Iridium undertakes no obligation to update or revise any forward-looking statements.

SOURCE Iridium Communications Inc.

Share this article

- Operations and supply chain executive with more than 20 years of experience spanning GMP manufacturing, global clinical and commercial supply, and gene therapy launch execution

- Former VP of Global Supply Chain and interim Chief Technical Officer at AveXis, where he built and led the global supply chain organization through the launch of Zolgensma® across more than 30 countries

- Appointment strengthens manufacturing and supply chain leadership as Nanoscope advances lead product MOGENRY™ through regulatory review toward potential global commercialization

DALLAS, Oct. 14, 2026 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the appointment of Troy Short as Senior Vice President, Manufacturing and Supply Chain. In this role, Short will lead Nanoscope's GMP manufacturing, commercial supply, and global distribution strategy as the company advances toward the potential approval and launch of MOGENRY™ (sonpiretigene isteparvovec; MCO-010).

Mr. Short brings more than two decades of operations and supply chain leadership across the pharmaceutical and gene therapy industries, with particular depth in building the manufacturing and distribution capabilities required to bring genetic medicines to patients. He previously served as Vice President of Global Supply Chain at AveXis, Inc., where he built and led the global commercial supply chain organization through the launch of Zolgensma®, scaling distribution globally, including the design of the specialized cold-chain model required for patient-specific delivery. He negotiated supply agreements, managed raw material sourcing, led the enterprise resource planning system implementation, and played a leadership role in FDA licensure and commercial readiness. Following the acquisition of AveXis by Novartis, he served as interim Chief Technical Officer during the transition.

Mr. Short subsequently served as Senior Vice President of Manufacturing and Supply Chain at Jaguar Gene Therapy, where he built Jaguar's CMC and supply chain organization, internalized process and analytical development, and directed the design of their GMP manufacturing facility. He later served as Chief Operating Officer of Advanced Medicine Partners, leading the design and startup of their GMP facility. Most recently, through his firm GTxConsulting, he has advised biotechnology companies and investment firms on CMC strategy, as well as supply chain and BLA readiness for gene therapies and other advanced modalities. Earlier in his career, Mr. Short spent 11 years at Hospira, a Pfizer company, as Director of Supply Chain for sterile pharmaceutical manufacturing.

"Troy has done what very few people in our industry have done: built and run the supply chain that delivered an approved AAV gene therapy to patients around the world," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope Therapeutics. "A one-time intravitreal therapy manufactured in the U.S. has to reach every patient who needs it, at quality, without interruption. That capability is built years in advance, and Troy knows exactly how to execute. His arrival at this stage reflects how seriously we are taking our preparation for launch."

Nanoscope continues to build clinical, regulatory, scaled-up manufacturing, and commercial-preparation momentum in support of MOGENRY for inherited retinal dystrophies (IRDs). The U.S. Food and Drug Administration (FDA) has accepted and filed the company's Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa (RP) with severe vision loss. The BLA is presently under FDA review. A Japan New Drug Application (JNDA) for MOGENRY is also currently under PMDA review for IRDs. These milestones reflect the company's expanding international regulatory pathway as it advances commercialization planning across key global markets.

"MOGENRY is designed to work regardless of the gene behind a patient's vision loss. My job is to make sure it reaches them," said Short. "My focus will be on strengthening our manufacturing partnerships, building a resilient commercial supply chain, and making sure patients and their physicians can count on product availability upon its potential approval."

About Inherited Retinal Dystrophies

Inherited retinal dystrophies (IRDs) are a genetically diverse group of rare disorders, caused by mutations in more than 250 genes, in which progressive loss of photoreceptor cells leads to impaired vision and, in most cases, complete blindness. IRDs include retinitis pigmentosa, the most common IRD, as well as Stargardt disease, cone-rod dystrophies, and Leber congenital amaurosis, among others. Because gene-specific therapies address only a single genetic cause, the vast majority of patients with IRDs have no approved treatment option.

About MOGENRY (sonpiretigene isteparvovec; MCO-010)

Nanoscope's multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope's Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team spent more than a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope's MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.

About Nanoscope Therapeutics

Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the company's BLA for MOGENRY, and the PMDA has accepted for priority review the company's Japan new drug application (JNDA) for MOGENRY for the treatment of IRDs. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial (NCT05417126) of MCO-010 in Stargardt disease (SD) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with Regenerative Medicine Advanced Therapy (RMAT) designation for SD, and European Medicines Agency (EMA) Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for IRDs in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other investigational new drug (IND)-ready programs include Leber congenital amaurosis (LCA). Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn. 

Contact:

Nanoscope Therapeutics Inc.

+1 (817) 857-1186

[email protected]

SOURCE Nanoscope Therapeutics

Share this article